News Deramiocel Achieves Statistical Significance in Phase 3 HOPE-3 Trial: 54% Slowing of Skeletal Disease Progression and Critical Cardiac Preservation Capricor Therapeutics’ pivotal data addresses previous regulatory hurdles, positioning the cell therapy as a first-in-class treatment for Duchenne cardiomyopathy.
News CervoMed’s Neflamapimod Reduces Plasma GFAP by 16% in DLB, Validating 'Bioavailability Hypothesis' for Phase 3 New biomarker data from the RewinD-LB extension confirms that optimized drug delivery reverses neuroinflammation, reviving the asset's commercial potential against a backdrop of unmet need.
